ZIMV Stock Forecast 2025-2026
Distance to ZIMV Price Targets
ZIMV Price Momentum
10 Quality Stocks Worth Considering Now
Researching ZimVie (ZIMV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ZIMV and similar high-potential opportunities.
Latest ZIMV Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ZIMV has a neutral consensus with a median price target of $15.50 (ranging from $15.00 to $16.00). The overall analyst rating is Hold (5.3/10). Currently trading at $11.75, the median forecast implies a 32.0% upside. This outlook is supported by 0 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 36.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZIMV Analyst Ratings
ZIMV Price Target Range
Latest ZIMV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZIMV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | Needham | David Saxon | Hold | Downgrade | $0.00 |
| Feb 27, 2025 | Needham | David Saxon | Buy | Reiterates | $23.00 |
| Aug 2, 2024 | Needham | David Saxon | Buy | Maintains | $23.00 |
| Jun 25, 2024 | Needham | David Saxon | Buy | Reiterates | $20.00 |
| May 16, 2024 | Needham | David Saxon | Buy | Upgrade | $0.00 |
| May 9, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Apr 11, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Mar 5, 2024 | Barclays | Matt Miksic | Underweight | Maintains | $16.00 |
| Jan 4, 2024 | Barclays | Matt Miksic | Underweight | Maintains | $13.00 |
| Dec 20, 2023 | JP Morgan | Robbie Marcus | Neutral | Maintains | $16.00 |
| Nov 16, 2023 | Needham | David Saxon | Hold | Initiates | $0.00 |
| Nov 2, 2023 | JP Morgan | Robbie Marcus | Neutral | Maintains | $10.00 |
| Aug 8, 2023 | Barclays | Matt Miksic | Underweight | Maintains | $11.00 |
| May 9, 2023 | Barclays | Matt Miksic | Underweight | Maintains | $7.00 |
| Mar 6, 2023 | Barclays | Matt Miksic | Underweight | Maintains | $5.00 |
| Dec 21, 2022 | Barclays | Matt Miksic | Underweight | Initiates | $9.00 |
| Jun 17, 2022 | JP Morgan | Robbie Marcus | Neutral | Initiates | $20.00 |
| Mar 18, 2022 | Guggenheim | Neutral | Initiates | $0.00 | |
| Mar 1, 2022 | Credit Suisse | Underperform | Initiates | $0.00 |
Zimvie Inc. (ZIMV) Competitors
The following stocks are similar to ZimVie based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zimvie Inc. (ZIMV) Financial Data
Zimvie Inc. has a market capitalization of $322.72M with a P/E ratio of -12.5x. The company generates $449.75M in trailing twelve-month revenue with a -5.7% profit margin.
Revenue growth is +8.0% quarter-over-quarter, while maintaining an operating margin of +1.5% and return on equity of -8.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Zimvie Inc. (ZIMV) Business Model
About Zimvie Inc.
Develops innovative medical devices for spine and dental markets.
Zimvie Inc. generates revenue through the design, development, and distribution of medical devices specifically tailored for spine and dental applications. By offering a range of products including implants, instruments, biologics, and digital dentistry solutions, the company meets the diverse needs of healthcare providers, thereby driving sales across hospitals, clinics, and dental practices.
Zimvie plays a crucial role in improving patient outcomes in orthopedics and dental care, positioning itself as a key player in the evolving medical technology and healthcare solutions landscape.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,770
CEO
Mr. Vafa Jamali
Country
United States
IPO Year
2022
Website
www.zimvie.comZimvie Inc. (ZIMV) Latest News & Analysis
ZimVie Inc. (Nasdaq: ZIMV) announced changes to its Board of Directors, impacting its leadership in the dental implant market. Further details on the changes were not provided.
Board changes at ZimVie may impact strategic direction and governance, influencing investor confidence and stock performance in the dental implant market.
Needham analysts indicate that Dentsply Sirona (XRAY) and ZimVie Inc. (ZIMV) are experiencing below-market growth with no significant upside potential.
Dentsply Sirona and ZimVie face stagnant growth and limited potential, signaling potential underperformance and risk for investors considering these stocks.
ZimVie Inc. (NASDAQ: ZIMV) will hold its Q4 2024 Earnings Conference Call on February 26, 2025, at 4:30 PM ET, featuring executives and analysts from various firms.
ZimVie's Q4 2024 earnings call signals potential updates on financial performance and strategic direction, influencing stock valuation and investor sentiment.
ZimVie Inc. (Nasdaq: ZIMV) reported its financial results for Q4 and the year ended December 31, 2024, and will host a conference call on February 26, 2025, at 4:30 p.m. ET.
ZimVie Inc.'s financial results can influence stock performance and investor sentiment, providing insights into its market position and growth prospects in the dental sector.
ZimVie to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
1 month agoZimVie Inc. (Nasdaq: ZIMV) will report Q4 and full-year 2024 financial results on February 26, 2025, after market close, with a conference call at 4:30 PM ET.
ZimVie Inc.'s upcoming financial results and conference call could impact stock performance, influencing investor sentiment and trading decisions based on earnings expectations.
ZimVie Announces Publication of a Study Supporting the Benefits of Its Implant Surface Technologies
1 month agoZimVie implants have been verified to meet essential roughness criteria, which may benefit long-term peri-implant health.
ZimVie's implants meeting critical roughness criteria enhances their marketability and potential for long-term success, positively impacting sales and investor confidence.
Frequently Asked Questions About ZIMV Stock
What is Zimvie Inc.'s (ZIMV) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Zimvie Inc. (ZIMV) has a median price target of $15.50. The highest price target is $16.00 and the lowest is $15.00.
Is ZIMV stock a good investment in 2025?
According to current analyst ratings, ZIMV has 0 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $11.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZIMV stock?
Wall Street analysts predict ZIMV stock could reach $15.50 in the next 12 months. This represents a 32.0% increase from the current price of $11.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zimvie Inc.'s business model?
Zimvie Inc. generates revenue through the design, development, and distribution of medical devices specifically tailored for spine and dental applications. By offering a range of products including implants, instruments, biologics, and digital dentistry solutions, the company meets the diverse needs of healthcare providers, thereby driving sales across hospitals, clinics, and dental practices.
What is the highest forecasted price for ZIMV Zimvie Inc.?
The highest price target for ZIMV is $16.00 from Matt Miksic at Barclays, which represents a 36.2% increase from the current price of $11.75.
What is the lowest forecasted price for ZIMV Zimvie Inc.?
The lowest price target for ZIMV is $15.00 from at , which represents a 27.7% increase from the current price of $11.75.
What is the overall ZIMV consensus from analysts for Zimvie Inc.?
The overall analyst consensus for ZIMV is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $15.50.
How accurate are ZIMV stock price projections?
Stock price projections, including those for Zimvie Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
